17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence
Key Takeaways
- Roughly 1 in 10 people who ever use cannabis develop cannabis use disorder, rising to about 1 in 6 among those who start in adolescence and higher still with daily use.
- The Cannabis Use Disorder Identification Test Revised (CUDIT-R) is an 8-item screen with a commonly used cutoff of 8 or more for hazardous use and 12 or more suggesting a probable disorder.
- No medication is FDA-approved for cannabis use disorder; N-acetylcysteine 1,200 mg twice daily has the strongest signal in adolescents and gabapentin has limited adult data.
- Combined motivational enhancement therapy, cognitive behavioral therapy and contingency management delivered over about 9 to 12 sessions is the best-supported psychosocial package.
- Cannabis withdrawal peaks between days 2 and 6, resolves over 1 to 2 weeks, and sleep disturbance with vivid dreams can persist for months and commonly drives relapse.
17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence
Quick Answer: About 1 in 10 people who ever use cannabis develop cannabis use disorder; about 1 in 6 among those who begin in adolescence; substantially higher among daily users. Screen with the CUDIT-R (8 items; 8 or more = hazardous use, 12 or more = probable disorder). No FDA-approved medication exists. The best-supported treatment is a combined package of motivational enhancement therapy, cognitive behavioral therapy and contingency management across roughly 9 to 12 sessions. N-acetylcysteine 1,200 mg twice daily has the strongest pharmacologic signal, primarily in adolescents.
1. Epidemiology That Frames the Conversation
| Population | Approximate risk of developing cannabis use disorder |
|---|---|
| Anyone who ever uses | About 10% |
| Onset in adolescence | About 17% |
| Daily or near-daily users | Roughly a third or more |
Other risk multipliers: high-potency product use, concentrate/dabbing route, co-occurring psychiatric illness, family history, and early age of first use. Cannabis is also the most commonly reported substance among adolescents entering treatment.
Framing that avoids a fight: "Most people who use cannabis never develop a problem. The people who do tend to have started young, use every day, or use high-potency products. Where do you fall on those three?"
2. Screening and Diagnosis
- CUDIT-R: 8 items covering frequency, hours spent stoned, inability to stop, failure to meet expectations, memory or concentration problems, use before driving or operating machinery, and whether anyone has expressed concern. 8 or more indicates hazardous use; 12 or more suggests a probable cannabis use disorder.
- CAST (Cannabis Abuse Screening Test): 6 items, widely used in adolescents and in Europe.
- DSM-5-TR: the standard 11 criteria with a 2 or more in 12 months threshold and severity by count (mild 2 to 3, moderate 4 to 5, severe 6 or more).
Assessment content that changes the plan: grams per day and product type; route (dabbing versus flower versus edible); time of first use each day; use before driving; whether the patient uses to sleep; and whether cannabis is being used to manage a treated or untreated psychiatric symptom.
3. Withdrawal
Cannabis withdrawal is a recognized DSM-5-TR diagnosis requiring 3 or more of seven features within about a week of cessation after heavy prolonged use: irritability/anger/aggression; nervousness or anxiety; sleep difficulty including vivid unpleasant dreams; decreased appetite or weight loss; restlessness; depressed mood; and at least one physical symptom such as abdominal pain, tremor, sweating, fever, chills or headache.
| Feature | Timing |
|---|---|
| Onset | 24 to 72 hours |
| Peak | Days 2 to 6 |
| Resolution of most symptoms | 1 to 2 weeks |
| Sleep disturbance and vivid dreams | Can persist weeks to months |
The clinically decisive point: withdrawal-related insomnia is the most common reason for relapse. Address sleep aggressively and early with sleep hygiene, stimulus control, cognitive behavioral therapy for insomnia where available, and short-term non-benzodiazepine options. Avoid benzodiazepines and Z-drugs given the co-use risk profile.
4. Psychosocial Treatment
| Approach | Evidence | Notes |
|---|---|---|
| MET + CBT, 9 to 12 sessions | The most consistently supported adult package | Brief 2-session MET produces smaller but real effects |
| Contingency management added to MET/CBT | Improves abstinence rates beyond MET/CBT alone | Same design rules as for stimulants: frequent, immediate, escalating |
| Multidimensional Family Therapy / Family-based therapies | First line for adolescents | Engages the family system rather than the adolescent alone |
| Adolescent Community Reinforcement Approach (A-CRA) | Well-supported for youth | Builds non-drug reinforcers |
| Brief interventions | Modest effects in non-treatment-seeking adults | Not sufficient for moderate or severe disorder |
5. Pharmacotherapy: What Is and Is Not Supported
| Agent | Evidence | Status |
|---|---|---|
| N-acetylcysteine 1,200 mg twice daily | Positive in an adolescent randomized trial; a larger adult trial did not replicate | Reasonable, low-risk adjunct, strongest case in adolescents |
| Gabapentin 1,200 mg/day | One small randomized trial showed reduced use and withdrawal | Limited; misuse potential in this population |
| Nabiximols and dronabinol (agonist substitution) | Reduce withdrawal severity and improve retention; abstinence effects less consistent | Nabiximols not available in the United States |
| Cannabidiol | Early trial data on reduced THC use | Investigational |
| Bupropion, SSRIs, atomoxetine, buspirone | Negative or inconsistent | Not recommended for the disorder itself |
| Quetiapine | Sedating; frequently prescribed off-label for sleep | Not an evidence-based treatment; weight and metabolic burden |
Practical stance for the exam: the correct answer for cannabis use disorder is almost always a structured psychosocial package, with medication used to target specific symptoms such as insomnia rather than the disorder as a whole.
An 18-year-old who has used cannabis daily since age 14 stops abruptly. On day 4 he reports irritability, anxiety, poor appetite, restlessness, and terrifying vivid dreams with severe insomnia. What is the most important treatment consideration?
An adult with moderate cannabis use disorder asks what medication will treat it. Which response is accurate?
Which figure best describes the risk of developing cannabis use disorder among people who begin using cannabis during adolescence?